Proactive Investors
20 Oct 2026, 06:44 UTC · 2h ago
Bunzl reiterates 2026 guidance after 4% underlying revenue growth
Impact · against what's priced in
Bunzl's reiteration of 2026 guidance and the modest Blueleaf acquisition provide stability but little catalyst for a valuation rerating. IXICO's reported acceleration in TechBio and AI-driven biomarker opportunities represent potential growth levers not yet fully quantified in current performance.
- IXI+0.30
No priced-in read yet
- In context
CEO Bram Goorden highlights accelerating growth and expanding opportunities in AI-driven biomarkers for Alzheimer's and Parkinson's diseases as part of the TechBio strategy.
Read from the article alone





